Hypoglycemia
Conditions
Brief summary
The trial is a single-centre, randomized, double-blind, phase 1b trial of multiple ascending doses of ZP4207 administered s.c. to healthy volunteers (HV) to evaluate the safety, tolerability, pharmakocinetic (PK) and pharmacodynamic (PD). Three cohorts of 8 subjects are planned. Within each cohort, the subjects will be randomly assigned to five repeated doses of ZP4207 or placebo in a 3:1 treatment allocation at trial site.
Interventions
DRUGZP4207
DRUGPlacebo
Sponsors
Zealand Pharma
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
MALE
Age
18 Years to 50 Years
Healthy volunteers
Yes
Inclusion criteria
1. Signed and dated informed consent obtained before any trial-related activities. (Trial-related activities are any procedures that would not have been performed during normal management of the subject). 2. Caucasian 3. Healthy male subject. 4. Age between 18 and 50 years, both inclusive. 5. Body weight between 70 and 90 kg (both inclusive) 6. Fasting plasma glucose concentration \<= 100 mg/dL. 7. Considered generally healthy upon completion of medical history, physical examination, vital signs, ECG and analysis of laboratory safety variables, as judged by the Investigator.
Exclusion criteria
1. Known or suspected hypersensitivity to IMP or related products. 2. Previous participation in this trial. Participation is defined as randomized. 3. Previous treatment with ZP4207. 4. Receipt of any medicinal product in clinical development within 3 months before randomization in this trial. 5. History of multiple and/or severe allergies to drugs or foods or a history of severe anaphylactic reaction. 6. Any history or presence of cancer except basal cell skin cancer or squamous cell skin cancer as judged by the Investigator. 7. Any history or presence of clinically relevant cardiovascular, pulmonary, respiratory, gastrointestinal, hepatic, renal, metabolic, endocrinological, haematological, dermatological, neurological, osteomuscular, articular, psychiatric, systemic, ocular, or infectious disease, or signs of acute illness as judged by the Investigator. 8. Any serious systemic infectious disease during four weeks prior to first dosing of the study drug, as judged by the Investigator. 9. Clinically significant abnormal values for haematology, biochemistry, coagulation, or urinalysis as judged by the Investigator. 10. Supine blood pressure at screening (after resting for at least 5 min in supine position) outside the ranges for systolic 95-140 mmHg blood pressure and for diastolic greater than 90 mmHg or symptoms and a heart rate at rest outside the range of 50-90 beats per minute (excluding white-coat hypertension; therefore, if a repeated measurement shows values within the range, the subject can be included in the trial). 11. Clinically significant abnormal standard 12-lead electrocardiogram (ECG) after 5 minutes resting in supine position at screening, as judged by the Investigator. 12. Significant history of alcoholism or drug abuse as judged by the Investigator or consuming more than 21 units of alcohol per week (one unit of alcohol equals about 250 mL of beer, one glass of wine of 120 mL, or 20 mL spirits). 13. A positive result in the alcohol and/or urine drug screen at the screening visit. 14. Smoker (defined as a subject who is smoking more than 7 cigarettes or the equivalent per week) within the last month prior to screening and who is not able or willing to refrain from smoking and use of nicotine substitute products one day before first dosing and during the treatment period. 15. Positive to the screening test for Hepatitis Bs antigen or Hepatitis C antibodies and/or a positive result to the test for HIV-1/2 antibodies or HIV-1 antigen. 16. Any medication (prescription and non-prescription drugs) within 14 days before IMP administration, with the exception of paracetamol or acetylsalicylic acid for occasional use to treat acute pain. 17. Blood donation or blood loss of more than 500 mL within the last 3 months. 18. Mental incapacity, unwillingness, or language barriers precluding adequate understanding or co-operation. 19. Male who is sexually active and not surgically sterilized who and whose partner(s) is not using adequate contraceptive methods (adequate contraceptive measures include surgical sterilisation, hormonal intrauterine devices \[coil\], oral hormonal contraceptives, each in combination with spermicide-coated condoms), or who is not willing to refrain from sexual intercourse from the first dosing until 1 month after last dosing in the trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants with adverse events | 28 days | Number of participants with adverse events |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Areas under the plasma concentration curve compared between first and last dosing | 5h | Areas under the plasma concentration curve from 0 until 300min |
| Plasma concentration curve compared between first and last dosing | 5 h | Maximum observed ZP4207 concentration |
| Pharmacokinetic endpoints compared between first and last dosing | 5 h | Apparent plasma clearance rate of ZP4207 estimated during the terminal phase |
| Pharmacodynamic endpoints compared between first and last dosing | 5 h | Area under the plasma glucose curve from 0 until 300min |
Countries
Germany
Outcome results
None listed